echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Over 450 million US dollars: Hausen introduces siRNA therapy for liver disease

    Over 450 million US dollars: Hausen introduces siRNA therapy for liver disease

    • Last Update: 2021-10-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 12, Hansen Pharmaceuticals and OliX Pharmaceuticals jointly announced that the two parties have signed a licensing and cooperation agreement to discover, develop and commercialize siRNA therapies for key targeted indications in China


    The two companies will use the GalNAc-asiRNA platform of OliX Pharmaceuticals and the strong R&D, production and commercialization capabilities of Hansen Pharmaceuticals Group in China to develop multiple hepatocyte-targeted products, including cardiovascular and metabolic And other indications


    According to the cooperation agreement, OliX Pharmaceuticals will use the GalNAc-asiRNA technology platform to discover lead drugs and ensure the development of drug candidates for specific targets, including cardiovascular, metabolic diseases and other liver-related diseases


    Down payment of US$6.


    OliX Pharmaceuticals is a clinical-stage pharmaceutical company.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.